Cd3 antibody biolegend il6

JCI Insight - IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function

TARM1 contributes to development of arthritis by activating dendritic cells through recognition of collagens

iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis - Cytotherapy

Monocyte-derived IL-6 programs microglia to rebuild damaged brain vasculature

Cells, Free Full-Text

CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci - ScienceDirect

Ultra-LEAF(TM) Purified anti-human CD3 300466 from BioLegend

CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity

Anti-IL-6 eluting immunomodulatory biomaterials prolong skin allograft survival

Anti Dog CD3 Antibody, clone CA17.2A12

FITC anti-human CD3 Antibody anti-CD3 - HIT3a

Frontiers IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function

Frontiers TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome

TH17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity

Engineering Bifunctional Antibodies with Constant Region Fusion Architectures